Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.54 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | BUB1 | O43683 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15385072 | 0.84 | CNR2 (0.60) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL516714 | 0.83 | CNR2 (0.59) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL516738 | 0.83 | CNR2 (0.67) | CNR2CNR1ACHEBUB1PTGER4 | |
| SCHEMBL1163283 | 0.75 | CNR2 (0.56) | CNR2CNR1ACHEMAPTSMN1; SMN2 | |
| SCHEMBL27800056 | 0.75 | CNR2 (0.80) | CNR2CNR1ACHESMN1; SMN2BUB1 | |
| SCHEMBL30310245 | 0.75 | MAPT (0.43) | CNR2CNR1ACHEMAPTSMN1; SMN2 | |
| SCHEMBL1943821 | 0.75 | MAPT (0.43) | CNR2CNR1ACHEMAPTSMN1; SMN2 | |
| SCHEMBL27761975 | 0.75 | MAPT (0.45) | MAPTSMN1; SMN2MEN1CRHBPKMT2A | |
| SCHEMBL3101505 | 0.75 | MAPT (0.45) | CNR2CNR1ACHEMAPTSMN1; SMN2 | |
| SCHEMBL27761974 | 0.75 | SCN9A (0.46) | CNR2MAPTSMN1; SMN2MEN1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2010079120-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | CNR2 3885/4885CNR1 4392/4885ACHE 1883/4885 |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | CNR2 3885/4885CNR1 4392/4885ACHE 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.